Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of antipsychotic drugs, caused by dopamine receptor blockade. It presents with high fever, severe muscle stiffness, altered mental status, and autonomic dysfunction. It can occur with both typical and atypical antipsychotics, as well as other dopamine-blocking drugs like certain antiemetics and lithium. NMS usually develops within days of starting or increasing a neuroleptic dose, or after sudden withdrawal of Parkinson’s medication. Prompt recognition, stopping the causative drug, supportive care, and specific treatments are essential for recovery.
Epidemiology
NMS is rare, affecting about 0.01% to 3.2% of people taking neuroleptic drugs. Its occurrence has declined thanks to newer antipsychotics, which pose a lower risk, and better recognition of the condition. It’s most often seen in young adults, likely because this age group is more often newly started on neuroleptics, not because of age itself. Men are affected about twice as often as women, mainly due to differing rates of exposure to these medications. In older adults, NMS is more commonly linked to the sudden stopping of dopaminergic drugs.
Anatomy
Pathophysiology
The exact mechanism behind NMS is not fully understood, but it mainly involves a sudden drop in dopamine activity in the brain, often from blocking D2 receptors or stopping dopamine-stimulating drugs abruptly. This dopamine disruption explains the hallmark signs like severe muscle stiffness, high fever, and altered mental status. Other neurotransmitters and sympathetic nervous system dysfunction also play a role. Some theories link NMS to calcium problems in muscle cells, similar to malignant hyperthermia. Reports of family clusters and genetic findings suggest that certain people may be genetically prone to developing NMS.
Etiology
All antipsychotic types, including typical and atypical agents, can trigger neuroleptic malignant syndrome (NMS), with haloperidol and chlorpromazine being the most common culprits; toxic lithium levels can also contribute. Major risk factors include high-potency or high-dose use, rapid dose increases, long-acting injections, prior NMS episodes, or recent catatonia. Young adult men are more often affected, likely due to greater exposure. Other risks include dehydration, agitation, poor nutrition, certain medical or psychiatric conditions, recent ECT, warm climates, inconsistent dosing, and possible genetic factors. If NMS occurs, restarting antipsychotics should be delayed to lower recurrence risk, with cautious reintroduction and a preference for switching drug classes or using atypical agents when possible.
Genetics
Prognostic Factors
In the past, NMS had a mortality rate of over 30%, but thanks to better awareness, early diagnosis, and improved supportive care, death rates have dropped to under 10%. When recognized and treated promptly, most patients recover completely within 2 to 14 days. However, delayed treatment can lead to serious complications like lasting catatonia, parkinsonism, or kidney and heart-lung problems. Fatal cases usually result from heart rhythm issues, blood clotting disorders, breathing failure, or kidney failure. Many patients can safely restart antipsychotics later, though some may experience recurrence. To reduce this risk, it’s recommended to wait at least two weeks after recovery before restarting, choose lower-potency drugs, begin with low doses and increase slowly, and avoid combining lithium with neuroleptics. Patients should stay well-hydrated and be closely monitored for any signs of NMS returning.
Clinical History
Age Group: Most cases occur in young adults (often ages 20–40), reflecting the age when people are typically first exposed to antipsychotic medications. Children and adolescents can develop NMS too; they tend to show more dystonia and less tremor compared to adults.
Physical Examination
Neuroleptic malignant syndrome (NMS) usually starts with severe muscle rigidity and progresses to high fever, unstable vital signs, and changes in consciousness, from confusion to coma. Children and adolescents may have more dystonia and less tremor than adults. Key signs include fever, sweating, drooling, rapid heart and breathing rates, blood pressure swings, low oxygen, incontinence, and dehydration; rare cases may mimic a heart attack. Due to dopamine blockade, patients show lead-pipe rigidity, swallowing difficulties, shuffling gait, tremors, dystonia, and involuntary movements, along with delirium, disorientation, hallucinations, and fluctuating alertness.
Age group
Associated comorbidity
The essential trigger is exposure to a neuroleptic (antipsychotic) drug, often soon after starting treatment or increasing the dose. Other risk factors can include dehydration, agitation, exhaustion, or underlying brain disorders that may predispose to NMS. Sudden withdrawal of dopaminergic medications in patients with Parkinson’s disease can also provoke NMS-like reactions.
Associated activity
Acuity of presentation
Onset is typically acute, developing over hours to days after neuroleptic exposure. Most cases emerge within 4–14 days of starting or increasing an antipsychotic; about 90% occur within the first 10 days, but NMS can occur anytime during treatment—even years later. Symptoms often progress rapidly over 24–72 hours, with mental status deteriorating from agitation and delirium to coma if untreated.
In emergency medicine, treating Neuroleptic Malignant Syndrome (NMS) involves a step-by-step approach to keep the patient safe and help them recover. The first and most important step is to stop the antipsychotic drug that caused the problem. Patients should then be moved to an ICU so they can be watched closely and given extra support if their breathing or blood pressure becomes unstable.
Doctors also use cooling methods like ice packs, cooling blankets, and chilled IV fluids to bring down the high fever, and they make sure the patient stays well-hydrated to avoid kidney problems. After these basic steps, medications are used to control severe muscle stiffness and other symptoms — this may include dantrolene, which relaxes muscles, and dopamine-boosting drugs like bromocriptine and amantadine to reverse the dopamine block that causes NMS.
If the NMS doesn’t get better with these treatments, Electroconvulsive Therapy (ECT) can be tried as a last option, especially for patients with severe catatonia or unstable vital signs when they cannot take antipsychotics again right away.
Finally, care is organized into phases: first, stabilizing the patient and stopping the drug; next, controlling symptoms with medication; then preventing serious complications like kidney failure or breathing trouble; and, once the patient is stable, slowly restarting any needed psychiatric medication, educating them to avoid dehydration or other triggers, and providing long-term follow-up to help prevent NMS from happening again.
Immediate discontinuation of the offending neuroleptic medication: The first and most crucial step is to stop all dopamine-blocking drugs (antipsychotics or other neuroleptics) as soon as NMS is suspected. Continuing these medications will worsen the dopamine blockade that underlies NMS. Stopping the drug often leads to gradual improvement over days.
Admit patient to ICU for close monitoring and supportive care: NMS can rapidly progress to life-threatening complications like respiratory failure, renal failure, arrhythmias, or DIC. ICU care allows for continuous cardiac monitoring, frequent vital signs, oxygen saturation monitoring, and prompt intervention if the patient deteriorates. Staff in the ICU are trained to manage complex cases needing ventilators, aggressive fluid management, and emergency procedures.
Provide circulatory and ventilatory support if needed: Circulatory support: IV fluids and vasopressors (if needed) help maintain blood pressure and perfusion, especially if dehydration or hypotension is present. Ventilatory support: Some patients develop severe muscle rigidity that affects breathing, excessive drooling, or altered consciousness that compromises the airway. In these cases, prophylactic intubation and mechanical ventilation are indicated to protect the airway and maintain oxygenation.
Use cooling measures: cooling blankets, ice packs, evaporative cooling, cooled IV fluids
Hyperthermia in NMS can reach dangerously high levels (>40°C).
Active cooling prevents heat-related organ damage.
Methods include:
Cooling blankets to lower core body temperature.
Ice packs placed in the axillae, groin, or neck.
Evaporative cooling: misting the skin with lukewarm water and using fans.
Cooled IV fluids help lower temperature internally.
Role of Muscle relaxant
Dantrolene sodium is a direct-acting skeletal muscle relaxant. It’s FDA-approved primarily for malignant hyperthermia (MH) a condition that has pathophysiological similarities to NMS (both involve uncontrolled calcium release and sustained muscle contraction). Because of its mechanism, it’s used off-label in NMS to help reduce severe muscle rigidity and hyperthermia.
Role of Dopamine agonists
Bromocriptine: It is a dopamine agonist, meaning it directly stimulates dopamine receptors in the brain. NMS is primarily caused by sudden, profound dopamine receptor blockades (especially D2 receptors) from antipsychotics. By activating dopamine receptors, bromocriptine helps reverse the dopamine deficit, reducing severe symptoms like muscle rigidity, fever, and altered mental status. The typical dosing is 2.5–10 mg orally 2–4 times daily, titrated to response.
Amantadine: It is an antiviral drug that also has dopaminergic properties. It works by enhancing dopamine release and blocking dopamine reuptake in the CNS. By boosting the amount of dopamine available, it partially counteracts the dopamine receptor blockade. This can ease rigidity, improve mental status, and help resolve autonomic symptoms. The typical dosing is 100–200 mg orally 2–3 times daily, adjusted for renal function.
Levodopa/Carbidopa: Levodopa is a dopamine precursor that crosses the blood–brain barrier and is then converted to dopamine.
Carbidopa is combined with levodopa to prevent its breakdown in the periphery, ensuring more dopamine reaches the brain. This is particularly valuable if NMS is triggered by abrupt withdrawal of anti-Parkinson medications (e.g., levodopa stopped suddenly). Restoring dopamine levels reduces rigidity, tremors, and autonomic symptoms. Typical dosing is individualized based on the patient’s usual Parkinson’s disease regimen.
Electroconvulsive Therapy (ECT) is a controlled medical procedure in which brief, carefully monitored electrical stimulation of the brain is used to trigger a generalized seizure. In Neuroleptic Malignant Syndrome (NMS), ECT is not considered a first-line treatment but may be used as a last resort when standard supportive care and medications such as dantrolene, bromocriptine, or amantadine have failed to produce improvement. It is particularly helpful in patients with severe catatonia that does not resolve, persistent autonomic instability with dangerously unstable heart rate or blood pressure despite intensive care, or when the underlying psychiatric condition, like severe psychosis, urgently requires management but antipsychotics cannot safely be restarted yet.
ECT helps by resetting disrupted neurotransmitter pathways, including the dopamine circuits that are significantly affected in NMS, and has been shown in case reports and series to lead to dramatic improvements in mental status, muscle rigidity, and autonomic symptoms when other treatments have failed. It is best considered for refractory NMS that does not improve after days of supportive care, in severe or life-threatening catatonia where the patient is nearly immobile, mute, or comatose, and in cases where immobility increases the risk of complications like respiratory failure, rhabdomyolysis, or blood clots.
The management of Neuroleptic Malignant Syndrome (NMS) can be viewed in clear phases: first, immediate stabilization, which includes stopping the causative neuroleptic drug and providing supportive care like hydration, cooling, and intensive monitoring; second, symptom control, using medications such as dantrolene, bromocriptine, or amantadine if needed to reduce rigidity and restore dopaminergic balance; third, complication prevention and monitoring, focusing on avoiding respiratory failure, renal injury, and other sequelae through ICU-level care; and finally, the recovery and reintegration phase, which includes patient education, cautious reintroduction of antipsychotics (if needed) at low doses, and long-term psychiatric follow-up to reduce the risk of recurrence.
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of antipsychotic drugs, caused by dopamine receptor blockade. It presents with high fever, severe muscle stiffness, altered mental status, and autonomic dysfunction. It can occur with both typical and atypical antipsychotics, as well as other dopamine-blocking drugs like certain antiemetics and lithium. NMS usually develops within days of starting or increasing a neuroleptic dose, or after sudden withdrawal of Parkinson’s medication. Prompt recognition, stopping the causative drug, supportive care, and specific treatments are essential for recovery.
NMS is rare, affecting about 0.01% to 3.2% of people taking neuroleptic drugs. Its occurrence has declined thanks to newer antipsychotics, which pose a lower risk, and better recognition of the condition. It’s most often seen in young adults, likely because this age group is more often newly started on neuroleptics, not because of age itself. Men are affected about twice as often as women, mainly due to differing rates of exposure to these medications. In older adults, NMS is more commonly linked to the sudden stopping of dopaminergic drugs.
The exact mechanism behind NMS is not fully understood, but it mainly involves a sudden drop in dopamine activity in the brain, often from blocking D2 receptors or stopping dopamine-stimulating drugs abruptly. This dopamine disruption explains the hallmark signs like severe muscle stiffness, high fever, and altered mental status. Other neurotransmitters and sympathetic nervous system dysfunction also play a role. Some theories link NMS to calcium problems in muscle cells, similar to malignant hyperthermia. Reports of family clusters and genetic findings suggest that certain people may be genetically prone to developing NMS.
All antipsychotic types, including typical and atypical agents, can trigger neuroleptic malignant syndrome (NMS), with haloperidol and chlorpromazine being the most common culprits; toxic lithium levels can also contribute. Major risk factors include high-potency or high-dose use, rapid dose increases, long-acting injections, prior NMS episodes, or recent catatonia. Young adult men are more often affected, likely due to greater exposure. Other risks include dehydration, agitation, poor nutrition, certain medical or psychiatric conditions, recent ECT, warm climates, inconsistent dosing, and possible genetic factors. If NMS occurs, restarting antipsychotics should be delayed to lower recurrence risk, with cautious reintroduction and a preference for switching drug classes or using atypical agents when possible.
In the past, NMS had a mortality rate of over 30%, but thanks to better awareness, early diagnosis, and improved supportive care, death rates have dropped to under 10%. When recognized and treated promptly, most patients recover completely within 2 to 14 days. However, delayed treatment can lead to serious complications like lasting catatonia, parkinsonism, or kidney and heart-lung problems. Fatal cases usually result from heart rhythm issues, blood clotting disorders, breathing failure, or kidney failure. Many patients can safely restart antipsychotics later, though some may experience recurrence. To reduce this risk, it’s recommended to wait at least two weeks after recovery before restarting, choose lower-potency drugs, begin with low doses and increase slowly, and avoid combining lithium with neuroleptics. Patients should stay well-hydrated and be closely monitored for any signs of NMS returning.
Age Group: Most cases occur in young adults (often ages 20–40), reflecting the age when people are typically first exposed to antipsychotic medications. Children and adolescents can develop NMS too; they tend to show more dystonia and less tremor compared to adults.
Neuroleptic malignant syndrome (NMS) usually starts with severe muscle rigidity and progresses to high fever, unstable vital signs, and changes in consciousness, from confusion to coma. Children and adolescents may have more dystonia and less tremor than adults. Key signs include fever, sweating, drooling, rapid heart and breathing rates, blood pressure swings, low oxygen, incontinence, and dehydration; rare cases may mimic a heart attack. Due to dopamine blockade, patients show lead-pipe rigidity, swallowing difficulties, shuffling gait, tremors, dystonia, and involuntary movements, along with delirium, disorientation, hallucinations, and fluctuating alertness.
The essential trigger is exposure to a neuroleptic (antipsychotic) drug, often soon after starting treatment or increasing the dose. Other risk factors can include dehydration, agitation, exhaustion, or underlying brain disorders that may predispose to NMS. Sudden withdrawal of dopaminergic medications in patients with Parkinson’s disease can also provoke NMS-like reactions.
Onset is typically acute, developing over hours to days after neuroleptic exposure. Most cases emerge within 4–14 days of starting or increasing an antipsychotic; about 90% occur within the first 10 days, but NMS can occur anytime during treatment—even years later. Symptoms often progress rapidly over 24–72 hours, with mental status deteriorating from agitation and delirium to coma if untreated.
In emergency medicine, treating Neuroleptic Malignant Syndrome (NMS) involves a step-by-step approach to keep the patient safe and help them recover. The first and most important step is to stop the antipsychotic drug that caused the problem. Patients should then be moved to an ICU so they can be watched closely and given extra support if their breathing or blood pressure becomes unstable.
Doctors also use cooling methods like ice packs, cooling blankets, and chilled IV fluids to bring down the high fever, and they make sure the patient stays well-hydrated to avoid kidney problems. After these basic steps, medications are used to control severe muscle stiffness and other symptoms — this may include dantrolene, which relaxes muscles, and dopamine-boosting drugs like bromocriptine and amantadine to reverse the dopamine block that causes NMS.
If the NMS doesn’t get better with these treatments, Electroconvulsive Therapy (ECT) can be tried as a last option, especially for patients with severe catatonia or unstable vital signs when they cannot take antipsychotics again right away.
Finally, care is organized into phases: first, stabilizing the patient and stopping the drug; next, controlling symptoms with medication; then preventing serious complications like kidney failure or breathing trouble; and, once the patient is stable, slowly restarting any needed psychiatric medication, educating them to avoid dehydration or other triggers, and providing long-term follow-up to help prevent NMS from happening again.
Emergency Medicine
Immediate discontinuation of the offending neuroleptic medication: The first and most crucial step is to stop all dopamine-blocking drugs (antipsychotics or other neuroleptics) as soon as NMS is suspected. Continuing these medications will worsen the dopamine blockade that underlies NMS. Stopping the drug often leads to gradual improvement over days.
Admit patient to ICU for close monitoring and supportive care: NMS can rapidly progress to life-threatening complications like respiratory failure, renal failure, arrhythmias, or DIC. ICU care allows for continuous cardiac monitoring, frequent vital signs, oxygen saturation monitoring, and prompt intervention if the patient deteriorates. Staff in the ICU are trained to manage complex cases needing ventilators, aggressive fluid management, and emergency procedures.
Provide circulatory and ventilatory support if needed: Circulatory support: IV fluids and vasopressors (if needed) help maintain blood pressure and perfusion, especially if dehydration or hypotension is present. Ventilatory support: Some patients develop severe muscle rigidity that affects breathing, excessive drooling, or altered consciousness that compromises the airway. In these cases, prophylactic intubation and mechanical ventilation are indicated to protect the airway and maintain oxygenation.
Use cooling measures: cooling blankets, ice packs, evaporative cooling, cooled IV fluids
Hyperthermia in NMS can reach dangerously high levels (>40°C).
Active cooling prevents heat-related organ damage.
Methods include:
Cooling blankets to lower core body temperature.
Ice packs placed in the axillae, groin, or neck.
Evaporative cooling: misting the skin with lukewarm water and using fans.
Cooled IV fluids help lower temperature internally.
Emergency Medicine
Dantrolene sodium is a direct-acting skeletal muscle relaxant. It’s FDA-approved primarily for malignant hyperthermia (MH) a condition that has pathophysiological similarities to NMS (both involve uncontrolled calcium release and sustained muscle contraction). Because of its mechanism, it’s used off-label in NMS to help reduce severe muscle rigidity and hyperthermia.
Emergency Medicine
Bromocriptine: It is a dopamine agonist, meaning it directly stimulates dopamine receptors in the brain. NMS is primarily caused by sudden, profound dopamine receptor blockades (especially D2 receptors) from antipsychotics. By activating dopamine receptors, bromocriptine helps reverse the dopamine deficit, reducing severe symptoms like muscle rigidity, fever, and altered mental status. The typical dosing is 2.5–10 mg orally 2–4 times daily, titrated to response.
Amantadine: It is an antiviral drug that also has dopaminergic properties. It works by enhancing dopamine release and blocking dopamine reuptake in the CNS. By boosting the amount of dopamine available, it partially counteracts the dopamine receptor blockade. This can ease rigidity, improve mental status, and help resolve autonomic symptoms. The typical dosing is 100–200 mg orally 2–3 times daily, adjusted for renal function.
Levodopa/Carbidopa: Levodopa is a dopamine precursor that crosses the blood–brain barrier and is then converted to dopamine.
Carbidopa is combined with levodopa to prevent its breakdown in the periphery, ensuring more dopamine reaches the brain. This is particularly valuable if NMS is triggered by abrupt withdrawal of anti-Parkinson medications (e.g., levodopa stopped suddenly). Restoring dopamine levels reduces rigidity, tremors, and autonomic symptoms. Typical dosing is individualized based on the patient’s usual Parkinson’s disease regimen.
Emergency Medicine
Electroconvulsive Therapy (ECT) is a controlled medical procedure in which brief, carefully monitored electrical stimulation of the brain is used to trigger a generalized seizure. In Neuroleptic Malignant Syndrome (NMS), ECT is not considered a first-line treatment but may be used as a last resort when standard supportive care and medications such as dantrolene, bromocriptine, or amantadine have failed to produce improvement. It is particularly helpful in patients with severe catatonia that does not resolve, persistent autonomic instability with dangerously unstable heart rate or blood pressure despite intensive care, or when the underlying psychiatric condition, like severe psychosis, urgently requires management but antipsychotics cannot safely be restarted yet.
ECT helps by resetting disrupted neurotransmitter pathways, including the dopamine circuits that are significantly affected in NMS, and has been shown in case reports and series to lead to dramatic improvements in mental status, muscle rigidity, and autonomic symptoms when other treatments have failed. It is best considered for refractory NMS that does not improve after days of supportive care, in severe or life-threatening catatonia where the patient is nearly immobile, mute, or comatose, and in cases where immobility increases the risk of complications like respiratory failure, rhabdomyolysis, or blood clots.
The management of Neuroleptic Malignant Syndrome (NMS) can be viewed in clear phases: first, immediate stabilization, which includes stopping the causative neuroleptic drug and providing supportive care like hydration, cooling, and intensive monitoring; second, symptom control, using medications such as dantrolene, bromocriptine, or amantadine if needed to reduce rigidity and restore dopaminergic balance; third, complication prevention and monitoring, focusing on avoiding respiratory failure, renal injury, and other sequelae through ICU-level care; and finally, the recovery and reintegration phase, which includes patient education, cautious reintroduction of antipsychotics (if needed) at low doses, and long-term psychiatric follow-up to reduce the risk of recurrence.
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of antipsychotic drugs, caused by dopamine receptor blockade. It presents with high fever, severe muscle stiffness, altered mental status, and autonomic dysfunction. It can occur with both typical and atypical antipsychotics, as well as other dopamine-blocking drugs like certain antiemetics and lithium. NMS usually develops within days of starting or increasing a neuroleptic dose, or after sudden withdrawal of Parkinson’s medication. Prompt recognition, stopping the causative drug, supportive care, and specific treatments are essential for recovery.
NMS is rare, affecting about 0.01% to 3.2% of people taking neuroleptic drugs. Its occurrence has declined thanks to newer antipsychotics, which pose a lower risk, and better recognition of the condition. It’s most often seen in young adults, likely because this age group is more often newly started on neuroleptics, not because of age itself. Men are affected about twice as often as women, mainly due to differing rates of exposure to these medications. In older adults, NMS is more commonly linked to the sudden stopping of dopaminergic drugs.
The exact mechanism behind NMS is not fully understood, but it mainly involves a sudden drop in dopamine activity in the brain, often from blocking D2 receptors or stopping dopamine-stimulating drugs abruptly. This dopamine disruption explains the hallmark signs like severe muscle stiffness, high fever, and altered mental status. Other neurotransmitters and sympathetic nervous system dysfunction also play a role. Some theories link NMS to calcium problems in muscle cells, similar to malignant hyperthermia. Reports of family clusters and genetic findings suggest that certain people may be genetically prone to developing NMS.
All antipsychotic types, including typical and atypical agents, can trigger neuroleptic malignant syndrome (NMS), with haloperidol and chlorpromazine being the most common culprits; toxic lithium levels can also contribute. Major risk factors include high-potency or high-dose use, rapid dose increases, long-acting injections, prior NMS episodes, or recent catatonia. Young adult men are more often affected, likely due to greater exposure. Other risks include dehydration, agitation, poor nutrition, certain medical or psychiatric conditions, recent ECT, warm climates, inconsistent dosing, and possible genetic factors. If NMS occurs, restarting antipsychotics should be delayed to lower recurrence risk, with cautious reintroduction and a preference for switching drug classes or using atypical agents when possible.
In the past, NMS had a mortality rate of over 30%, but thanks to better awareness, early diagnosis, and improved supportive care, death rates have dropped to under 10%. When recognized and treated promptly, most patients recover completely within 2 to 14 days. However, delayed treatment can lead to serious complications like lasting catatonia, parkinsonism, or kidney and heart-lung problems. Fatal cases usually result from heart rhythm issues, blood clotting disorders, breathing failure, or kidney failure. Many patients can safely restart antipsychotics later, though some may experience recurrence. To reduce this risk, it’s recommended to wait at least two weeks after recovery before restarting, choose lower-potency drugs, begin with low doses and increase slowly, and avoid combining lithium with neuroleptics. Patients should stay well-hydrated and be closely monitored for any signs of NMS returning.
Age Group: Most cases occur in young adults (often ages 20–40), reflecting the age when people are typically first exposed to antipsychotic medications. Children and adolescents can develop NMS too; they tend to show more dystonia and less tremor compared to adults.
Neuroleptic malignant syndrome (NMS) usually starts with severe muscle rigidity and progresses to high fever, unstable vital signs, and changes in consciousness, from confusion to coma. Children and adolescents may have more dystonia and less tremor than adults. Key signs include fever, sweating, drooling, rapid heart and breathing rates, blood pressure swings, low oxygen, incontinence, and dehydration; rare cases may mimic a heart attack. Due to dopamine blockade, patients show lead-pipe rigidity, swallowing difficulties, shuffling gait, tremors, dystonia, and involuntary movements, along with delirium, disorientation, hallucinations, and fluctuating alertness.
The essential trigger is exposure to a neuroleptic (antipsychotic) drug, often soon after starting treatment or increasing the dose. Other risk factors can include dehydration, agitation, exhaustion, or underlying brain disorders that may predispose to NMS. Sudden withdrawal of dopaminergic medications in patients with Parkinson’s disease can also provoke NMS-like reactions.
Onset is typically acute, developing over hours to days after neuroleptic exposure. Most cases emerge within 4–14 days of starting or increasing an antipsychotic; about 90% occur within the first 10 days, but NMS can occur anytime during treatment—even years later. Symptoms often progress rapidly over 24–72 hours, with mental status deteriorating from agitation and delirium to coma if untreated.
In emergency medicine, treating Neuroleptic Malignant Syndrome (NMS) involves a step-by-step approach to keep the patient safe and help them recover. The first and most important step is to stop the antipsychotic drug that caused the problem. Patients should then be moved to an ICU so they can be watched closely and given extra support if their breathing or blood pressure becomes unstable.
Doctors also use cooling methods like ice packs, cooling blankets, and chilled IV fluids to bring down the high fever, and they make sure the patient stays well-hydrated to avoid kidney problems. After these basic steps, medications are used to control severe muscle stiffness and other symptoms — this may include dantrolene, which relaxes muscles, and dopamine-boosting drugs like bromocriptine and amantadine to reverse the dopamine block that causes NMS.
If the NMS doesn’t get better with these treatments, Electroconvulsive Therapy (ECT) can be tried as a last option, especially for patients with severe catatonia or unstable vital signs when they cannot take antipsychotics again right away.
Finally, care is organized into phases: first, stabilizing the patient and stopping the drug; next, controlling symptoms with medication; then preventing serious complications like kidney failure or breathing trouble; and, once the patient is stable, slowly restarting any needed psychiatric medication, educating them to avoid dehydration or other triggers, and providing long-term follow-up to help prevent NMS from happening again.
Emergency Medicine
Immediate discontinuation of the offending neuroleptic medication: The first and most crucial step is to stop all dopamine-blocking drugs (antipsychotics or other neuroleptics) as soon as NMS is suspected. Continuing these medications will worsen the dopamine blockade that underlies NMS. Stopping the drug often leads to gradual improvement over days.
Admit patient to ICU for close monitoring and supportive care: NMS can rapidly progress to life-threatening complications like respiratory failure, renal failure, arrhythmias, or DIC. ICU care allows for continuous cardiac monitoring, frequent vital signs, oxygen saturation monitoring, and prompt intervention if the patient deteriorates. Staff in the ICU are trained to manage complex cases needing ventilators, aggressive fluid management, and emergency procedures.
Provide circulatory and ventilatory support if needed: Circulatory support: IV fluids and vasopressors (if needed) help maintain blood pressure and perfusion, especially if dehydration or hypotension is present. Ventilatory support: Some patients develop severe muscle rigidity that affects breathing, excessive drooling, or altered consciousness that compromises the airway. In these cases, prophylactic intubation and mechanical ventilation are indicated to protect the airway and maintain oxygenation.
Use cooling measures: cooling blankets, ice packs, evaporative cooling, cooled IV fluids
Hyperthermia in NMS can reach dangerously high levels (>40°C).
Active cooling prevents heat-related organ damage.
Methods include:
Cooling blankets to lower core body temperature.
Ice packs placed in the axillae, groin, or neck.
Evaporative cooling: misting the skin with lukewarm water and using fans.
Cooled IV fluids help lower temperature internally.
Emergency Medicine
Dantrolene sodium is a direct-acting skeletal muscle relaxant. It’s FDA-approved primarily for malignant hyperthermia (MH) a condition that has pathophysiological similarities to NMS (both involve uncontrolled calcium release and sustained muscle contraction). Because of its mechanism, it’s used off-label in NMS to help reduce severe muscle rigidity and hyperthermia.
Emergency Medicine
Bromocriptine: It is a dopamine agonist, meaning it directly stimulates dopamine receptors in the brain. NMS is primarily caused by sudden, profound dopamine receptor blockades (especially D2 receptors) from antipsychotics. By activating dopamine receptors, bromocriptine helps reverse the dopamine deficit, reducing severe symptoms like muscle rigidity, fever, and altered mental status. The typical dosing is 2.5–10 mg orally 2–4 times daily, titrated to response.
Amantadine: It is an antiviral drug that also has dopaminergic properties. It works by enhancing dopamine release and blocking dopamine reuptake in the CNS. By boosting the amount of dopamine available, it partially counteracts the dopamine receptor blockade. This can ease rigidity, improve mental status, and help resolve autonomic symptoms. The typical dosing is 100–200 mg orally 2–3 times daily, adjusted for renal function.
Levodopa/Carbidopa: Levodopa is a dopamine precursor that crosses the blood–brain barrier and is then converted to dopamine.
Carbidopa is combined with levodopa to prevent its breakdown in the periphery, ensuring more dopamine reaches the brain. This is particularly valuable if NMS is triggered by abrupt withdrawal of anti-Parkinson medications (e.g., levodopa stopped suddenly). Restoring dopamine levels reduces rigidity, tremors, and autonomic symptoms. Typical dosing is individualized based on the patient’s usual Parkinson’s disease regimen.
Emergency Medicine
Electroconvulsive Therapy (ECT) is a controlled medical procedure in which brief, carefully monitored electrical stimulation of the brain is used to trigger a generalized seizure. In Neuroleptic Malignant Syndrome (NMS), ECT is not considered a first-line treatment but may be used as a last resort when standard supportive care and medications such as dantrolene, bromocriptine, or amantadine have failed to produce improvement. It is particularly helpful in patients with severe catatonia that does not resolve, persistent autonomic instability with dangerously unstable heart rate or blood pressure despite intensive care, or when the underlying psychiatric condition, like severe psychosis, urgently requires management but antipsychotics cannot safely be restarted yet.
ECT helps by resetting disrupted neurotransmitter pathways, including the dopamine circuits that are significantly affected in NMS, and has been shown in case reports and series to lead to dramatic improvements in mental status, muscle rigidity, and autonomic symptoms when other treatments have failed. It is best considered for refractory NMS that does not improve after days of supportive care, in severe or life-threatening catatonia where the patient is nearly immobile, mute, or comatose, and in cases where immobility increases the risk of complications like respiratory failure, rhabdomyolysis, or blood clots.
The management of Neuroleptic Malignant Syndrome (NMS) can be viewed in clear phases: first, immediate stabilization, which includes stopping the causative neuroleptic drug and providing supportive care like hydration, cooling, and intensive monitoring; second, symptom control, using medications such as dantrolene, bromocriptine, or amantadine if needed to reduce rigidity and restore dopaminergic balance; third, complication prevention and monitoring, focusing on avoiding respiratory failure, renal injury, and other sequelae through ICU-level care; and finally, the recovery and reintegration phase, which includes patient education, cautious reintroduction of antipsychotics (if needed) at low doses, and long-term psychiatric follow-up to reduce the risk of recurrence.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
